Development and validation of the self-reported disability status scale (SRDSS) to estimate EDSS-categories.
- Kaufmann M Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: marco.kaufmann@uzh.ch.
- Salmen A Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland. Electronic address: anke.salmen@insel.ch.
- Barin L Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland; FBK-IRVAPP, Research Institute for the Evaluation of Public Policies, Bruno Kessler Foundation, Trento, Italy. Electronic address: laura.barin@gmail.com.
- Puhan MA Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: miloalan.puhan@uzh.ch.
- Calabrese P Division of Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland. Electronic address: pasquale.calabrese@unibas.ch.
- Kamm CP Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; Neurocentre, Luzerner Kantonsspital, Luzern, Switzerland. Electronic address: christian.kamm@luks.ch.
- Gobbi C Faculty of biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland; Department of Neurology, Multiple Sclerosis Center (MSC), Neurocenter of Southern Switzerland, Lugano, Switzerland. Electronic address: Claudio.Gobbi@eoc.ch.
- Kuhle J Neurologic Clinic and Policlinic, University Hospital and University of Basel, Departments of Medicine, Biomedicine and Clinical Research, Basel, Switzerland. Electronic address: Jens.Kuhle@usb.ch.
- Manjaly ZM Department of Neurology, Schulthess Clinic, Zürich, Switzerland; Department of Health Sciences and Technology, ETH Zurich, Zürich, Switzerland. Electronic address: Zina-Mary.Manjaly@kws.ch.
- Ajdacic-Gross V Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: vajdacic@dgsp.uzh.ch.
- Schafroth S Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: sandra.schafroth2@uzh.ch.
- Bottignole B Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: b.bottignole@neurozentrumbellevue.ch.
- Ammann S Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: sabin.ammann@uzh.ch.
- Zecca C Faculty of biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland; Department of Neurology, Multiple Sclerosis Center (MSC), Neurocenter of Southern Switzerland, Lugano, Switzerland. Electronic address: Chiara.Zecca@eoc.ch.
- D'Souza M Neurologic Clinic and Policlinic, University Hospital and University of Basel, Departments of Medicine, Biomedicine and Clinical Research, Basel, Switzerland. Electronic address: marcus.dsouza@usb.ch.
- von Wyl V Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. Electronic address: viktor.vonwyl@uzh.ch.
- 2020-05-07
Published in:
- Multiple sclerosis and related disorders. - 2020
English
BACKGROUND
Clinician-assessed Expanded Disease Status Scale (EDSS) is gold standard in clinical investigations but normally unavailable in population-based, patient-centred MS-studies. Our objective was to develop a self-reported gait measure reflecting EDSS-categories.
METHODS
We developed the self-reported disability status scale (SRDSS) with three categories (≤3.5, 4-6.5, ≥7) based on three mobility-related questions. The SRDSS was determined for 173 persons with MS and validated against clinical EDSS to calculate sensitivity and specificity.
RESULTS
Accuracy was 88.4% (153 correctly classified) and weighted kappa 0.73 (0.62-0.84). Sensitivity/specificity-pairs were 94.5%/77.8%, 69.0%/94.7% and 100%/98.2% for SRDSS ≤3.5, 4-6.5 and ≥7, respectively.
CONCLUSIONS
Self-reported SRDSS approximates EDSS-categories well and fosters comparability between clinical and population-based studies.
Clinician-assessed Expanded Disease Status Scale (EDSS) is gold standard in clinical investigations but normally unavailable in population-based, patient-centred MS-studies. Our objective was to develop a self-reported gait measure reflecting EDSS-categories.
METHODS
We developed the self-reported disability status scale (SRDSS) with three categories (≤3.5, 4-6.5, ≥7) based on three mobility-related questions. The SRDSS was determined for 173 persons with MS and validated against clinical EDSS to calculate sensitivity and specificity.
RESULTS
Accuracy was 88.4% (153 correctly classified) and weighted kappa 0.73 (0.62-0.84). Sensitivity/specificity-pairs were 94.5%/77.8%, 69.0%/94.7% and 100%/98.2% for SRDSS ≤3.5, 4-6.5 and ≥7, respectively.
CONCLUSIONS
Self-reported SRDSS approximates EDSS-categories well and fosters comparability between clinical and population-based studies.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1016/j.msard.2020.102148
- PMID 32371376
- Persistent URL
- https://sonar.ch/global/documents/201668
Statistics
Document views: 29
File downloads:
- Full-text: 0